Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study evaluating ONO-4538 (nivolumab) in combination with ipilimumab and chemotherapy for chemotherapy-naïve pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Junction Cancer
• Gastric Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Nivolumab (ONO-4538) (nivolumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING